Literature DB >> 12429477

A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.

Marjan Bouma1, Bastiaan Nuijen, Martine T Jansen, Gianni Sava, Antonella Flaibani, Auke Bult, Jos H Beijnen.   

Abstract

NAMI-A is a novel ruthenium complex with selective activity against cancer metastases currently in Phase I clinical trials in The Netherlands. The chemical stability of this new agent was investigated utilizing a stability-indicating reversed-phase high performance liquid chromatographic assay with ultraviolet detection and ultraviolet/visible light spectrophotometry. The degradation kinetics of NAMI-A were studied as a function of pH, buffer composition, and temperature. Degradation of NAMI-A follows first-order kinetics at pH<6 and zero-order kinetics at pH > or =6. A pH-rate profile, employing rate constants extrapolated to zero buffer concentration, was constructed, demonstrating that NAMI-A is most stable in pH region 3-4. The degradation rate is not significantly affected by specific buffer components. Storage temperature strongly influences the degradation rate.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12429477     DOI： 10.1016/s0378-5173(02)00460-x

Source DB:  PubMed          Journal:  Int J Pharm        ISSN： 0378-5173            Impact factor:   5.875


  9 in total

1.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

2.  Reactions of Ru(III)-drugs KP1019 and KP418 with guanine, 2'-deoxyguanosine and guanosine: a DFT study.

Authors:  Pramod Kumar Shah; Nihar R Jena; Pradeep Kumar Shukla
Journal:  J Mol Model       Date:  2022-09-05       Impact factor: 2.172

3.  Electronic structural investigations of ruthenium compounds and anticancer prodrugs.

Authors:  Travis V Harris; Robert K Szilagyi; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2009-04-07       Impact factor: 3.358

4.  The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.

Authors:  Malgorzata Brindell; Iwona Stawoska; Justyna Supel; Andrzej Skoczowski; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2008-04-26       Impact factor: 3.358

5.  Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.

Authors:  Angela Casini; Guido Mastrobuoni; Mattia Terenghi; Chiara Gabbiani; Enrico Monzani; Gloriano Moneti; Luigi Casella; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2007-08-07       Impact factor: 3.358

6.  Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution.

Authors:  Malgorzata Brindell; Dorota Piotrowska; Azza A Shoukry; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2007-05-15       Impact factor: 3.358

7.  Dimethyl sulfoxide promotes the multiple functions of the tumor suppressor HLJ1 through activator protein-1 activation in NSCLC cells.

Authors:  Chi-Chung Wang; Sheng-Yi Lin; Yi-Hua Lai; Ya-Jung Liu; Yuan-Lin Hsu; Jeremy J W Chen
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

Review 8.  Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.

Authors:  Claudia Riccardi; Domenica Musumeci; Marco Trifuoggi; Carlo Irace; Luigi Paduano; Daniela Montesarchio
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-26

Review 9.  Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Francesco Maione; Daniela Montesarchio; Michele Caraglia; Luigi Paduano; Rita Santamaria; Carlo Irace
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.